DMAC vs USB
DiaMedica Therapeutics Inc (DMAC) versus U.S. Bancorp (USB) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
U.S. Bancorp (USB) is a banks - regional company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported USB revenue for 2025-12-31 was $28.66B. Net income was $7.57B. Revenue was up 4.4% from 2024-12-31 to 2025-12-31. USB currently screens at market cap $74.68B and trailing P/E 11.9.
DMAC currently screens at market cap $157.4M. USB currently screens at market cap $74.68B and trailing P/E 11.9.
Not investment advice. Open the DMAC and USB stock pages for the full models.
Not investment advice.